Rodin Therapeutics discovers and develops therapeutics by applying chemical strategies to target protein complexes that selectively modulate gene expression. On November 18, 2019, Rodin Therapeutics was acquired by Alkermes at a valuation of $100M.
Company (Acquired)
Phone:
101 Huntington Avenue
21st Floor, Suite 2150
Boston, 02199
Massachusetts, United States
Per Week | Per Month | Per 6 Months | Per Year | |
---|---|---|---|---|
Rank | Login to see details | |||
Page Views Per Million | Login to see details | |||
Page Views Per User | Login to see details | |||
Reach Per Million | Login to see details |
Investor | Investor Type | Location | Participating Rounds |
---|---|---|---|
Google Ventures | Corporate Venture | Mountain View, California, United States | Series B - II |
Atlas Venture | Venture Capital | Cambridge, Massachusetts, United States | Series B - II, Series B, Series A, Seed VC |
Biogen Idec New Ventures | Corporate Venture | Cambridge, Massachusetts, United States | Series B |
Hatteras Venture Partners | Venture Capital | Durham, North Carolina, United States | Series B - II |
Johnson & Johnson Innovation | Corporate Venture | New Brunswick, New Jersey, United States | Series A, Seed VC |
Title | Application Date | Patent Date | Status (Patent / Application) |
---|---|---|---|
Bicyclic inhibitors of histone deacetylase | Jan 11, 2018 | Oct 06, 2020 | Patent |
Bicyclic inhibitors of histone deacetylase | Nov 12, 2019 | Jun 30, 2020 | Patent |
Bicyclic inhibitors of histone deacetylase | Mar 23, 2018 | Dec 31, 2019 | Patent |
Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase | Jul 05, 2016 | Sep 24, 2019 | Patent |
Inhibitors of histone deacetylase | Jun 25, 2015 | May 29, 2018 | Patent |